P/E Ratio Insights for Regeneron Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals Inc.'s stock price is currently at $830.00, after a 0.13% decrease. However, over the past month, the stock increased by 1.13%, and in the past year, by 14.93%. The company's P/E ratio is lower than the aggregate P/E of the Biotechnology industry, which could indicate that the stock is undervalued or that shareholders do not expect future growth.
October 06, 2023 | 7:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' stock price is at $830.00, with a lower P/E ratio than the Biotech industry. This could indicate undervaluation or low growth expectations.
Regeneron Pharmaceuticals' P/E ratio is lower than the aggregate P/E of the Biotechnology industry. This could indicate that the stock is undervalued, which would be a positive for the stock price. However, it could also suggest that shareholders do not expect future growth, which would be a negative. Therefore, the impact on the stock price in the short term is uncertain.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100